Flux Peptides
$0.00 0

Cart

No products in the cart.

Tesamorelin research peptide vial
Three Tesamorelin research peptide vials

Tesamorelin

$90.00

Tesamorelin is a synthetic analog of human growth hormone releasing factor (GRF, also called GHRH). It consists of the 44 amino acid human GRF sequence with a hexenoyl group attached to the tyrosine residue at the N terminus. Tesamorelin is the active ingredient of the prescription medicines Egrifta and Egrifta WR. The lyophilized material on this page is a research chemical: it is not Egrifta, it is not Egrifta WR, and no tesamorelin product is currently marketed in Canada.

  • Shipping: Dispatched from within Canada
  • Purity: greater than or equal to 99.0 percent (HPLC tested)
  • Format: Lyophilized powder for laboratory research
  • Key Research Focus: GHRH receptor signalling, visceral adipose tissue and IGF-1
  • Storage: Store at minus 20 degrees Celsius, sealed and protected from light and moisture
SKU: FLX-TESA-10MG Category:

Description

Tesamorelin (GHRH Analog)

Tesamorelin is a synthetic peptide analog of human growth hormone releasing factor (GRF, also referred to as growth hormone releasing hormone or GHRH). The FDA label describes it as the 44 amino acid sequence of human GRF carrying a hexenoyl moiety, a six carbon chain with a double bond at position 3, attached to the tyrosine residue at the N terminal part of the molecule. This N terminal modification has been reported to slow degradation by dipeptidyl peptidase 4 (DPP-4) relative to unmodified GRF.

Regulatory status

Tesamorelin is an approved prescription medicine in the United States. The FDA approved Egrifta (application 022505, Theratechnologies) on November 10, 2010 as a new molecular entity, and the label indication reads: Egrifta is indicated for the reduction of excess abdominal fat in HIV infected adult patients with lipodystrophy. On March 25, 2025 the FDA approved a supplement to the same application covering Egrifta WR, the more concentrated F8 formulation, for the same indication.

In Canada, Health Canada’s Drug Product Database lists both Egrifta records under Theratechnologies as cancelled. DIN 02438712 is recorded as Cancelled Post Market with a status date of September 30, 2022, and DIN 02423677 is recorded as Cancelled Pre Market with a status date of July 13, 2023. No tesamorelin product is currently authorized for sale in Canada.

The material offered on this page is a laboratory research chemical. It is not Egrifta, it is not Egrifta WR, it is not a licensed or authorized medicine in Canada or any other country, and it is not supplied for any medical purpose.

Technical Specifications

  • Peptide name: Tesamorelin
  • Synonyms: TH9507, trans-3-hexenoyl human GRF(1 to 44), tesamorelin acetate
  • CAS number: 218949-48-5
  • Molecular formula: C221H366N72O67S (free peptide; the approved medicine is formulated as the acetate salt)
  • Molar mass: 5135.9 g/mol (free base equivalent, per the FDA label)
  • Purity: greater than or equal to 99.0 percent (determined by HPLC)
  • Appearance: White lyophilized powder
  • Solubility: Soluble in sterile water

Research Context

Published work on tesamorelin concerns the pituitary growth hormone axis:

  • GHRH receptor agonism: tesamorelin has been studied as an agonist at the GHRH receptor in the anterior pituitary, where GRF normally stimulates the synthesis and secretion of growth hormone.
  • Visceral adipose tissue: the registrational clinical programme measured change in visceral adipose tissue by computed tomography in HIV infected adults with lipodystrophy, which is the basis of the approved indication described above.
  • IGF-1: studies have tracked circulating insulin like growth factor 1 as a downstream marker of growth hormone release.
  • Glucose and lipid measures: clinical studies have also monitored glucose and lipid parameters. These are monitored endpoints in the published literature and are not presented here as effects of the research material.

Storage and Handling

  • Lyophilized powder: store at minus 20 degrees Celsius (minus 4 degrees Fahrenheit) for up to 36 months, sealed and protected from light, ultraviolet light and moisture.
  • Reconstituted solution: store at 4 degrees Celsius (39 degrees Fahrenheit), protected from light, for up to 14 to 21 days. Avoid vigorous agitation and repeated freeze and thaw cycles of the solution.
  • Handling: standard laboratory safety practice applies. This product is for laboratory research use only.

Testing and Quality Control

Every batch of Tesamorelin undergoes:

  1. HPLC (high performance liquid chromatography): purity reported as greater than or equal to 99.0 percent.
  2. MS (mass spectrometry): confirms the molecular mass expected for the N terminally modified 44 residue sequence.
  3. Visual inspection of the lyophilized cake and container on receipt in Canada.

HPLC and mass spectrometry characterize chemical purity and identity. They do not measure biological activity, and no potency testing is performed or implied.

For laboratory research use only. Not for human or veterinary use.

Further reading